Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDCA for fibromyalgia
MOH_2026-03-11_015708Phase 2Not yet recruiting
- Sponsor
- ד"ר אמיר מינרבי
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ursodeoxycholic acid in fibromyalgia (FM), sponsored by ד"ר אמיר מינרבי. Primary endpoint: Pain intensity reduction. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on MOH_2026-03-11_015708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-11_015708.